# Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C

> **NCT03022006** · PHASE4 · UNKNOWN · sponsor: **Norte Study Group** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** elbasvir, grazoprevir

## Key facts

- **NCT ID:** NCT03022006
- **Lead sponsor:** Norte Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-15
- **Primary completion:** 2019-03
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03022006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03022006, "Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03022006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*